[5 min watch] Skin Cancer Update with Prof Giuseppe Argenziano [March 2020]

In this month’s skin cancer update video, Professor Giuseppe Argenziano talks about the criteria for sentinel node biopsies in melanoma patients. Using real patient case examples, he gives practical advice for how best to assess these patients to optimise their outcomes while avoiding unnecessary procedures.

Watch the full skin cancer update now:


To learn more from Prof Giuseppe Argenziano:

Skin Cancer Certificate Courses in Australia

 

 

 


More skin cancer updates from Prof Giuseppe Argenziano:

4 comments on “[5 min watch] Skin Cancer Update with Prof Giuseppe Argenziano [March 2020]

  1. I downloaded the app…but it is in Italian…and I can’t seem to find a way to translate it into English…is there another app?…or can u tell me how to change it to english.

    thank you

    1. Hi Bronnie, thanks for your comment. We contacted the app developer and the app is currently only available in Italian. The English version is in production. Sorry for the inconvenience.

      Warm regards, Abbie | HealthCert

  2. Hi Giuseppe, you say in the recording that “sentinel node biopsy is recommended from stage 1B” and “stage 1B is a melanoma which is 0.8 mm or higher.”

    When I use MelApp for a 0.9 mm melanoma with absent ulceration, it is reported as stage 1A, which is consistent with AJCC pathological staging.
    However, when I use the AJCC clinical staging it would stage this as 1B.

    In a primary care setting I would be using the clinical staging criteria (ie. assess the histology of the melanoma report, and perform a clinical lymph node examination) to assess the need for SLNB.

    I don’t imagine anyone who had pathological staging ie. Has pathologic information about the lymph nodes from partial or complete lymphadenectomy would require a SLNB.

    If you would please clarify:
    1) Would using the MelApp lead a doctor with a 0.9mm melanoma to stage this as 1A and not 1B which would lead to a difference between performing SLNB.

    2) Do you mean from your earlier comments that all stage 1B melanomas (Breslow 0.8-1.0 mm w/o ulceration as well as ≤ 1.0 mm w/ ulceration), should have SLNB? Eg. A melanoma 0.3 mm with ulceration should be referred for SLNB?

    1. Hello Jeremy, thanks so much for your comment. I reply on Giuseppe’s behalf.

      1) Would using the MelApp lead a doctor with a 0.9mm melanoma to stage this as 1A and not 1B which would lead to a difference between performing SLNB.
      No, clinical stage 1b include a 0.9 mm melanoma that is advised to perform SLNB. Once SLNB is eventually negative, then the final pathologic stage goes to 1A.

      2) Do you mean from your earlier comments that all stage 1B melanomas (Breslow 0.8-1.0 mm w/o ulceration as well as ≤ 1.0 mm w/ ulceration), should have SLNB? Eg. A melanoma 0.3 mm with ulceration should be referred for SLNB?
      Yes, that’s what it is recommended.

Leave a Reply

Your email address will not be published. Required fields are marked *